杭州天玑济世生物科技

Tianji Jishi Biotechnology is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the development of next-generation immune cell therapies for solid tumors. The company utilizes its proprietary TCR-like antibody discovery platform to target intracellular tumor antigens that are traditionally considered undruggable. By recognizing peptide-MHC complexes, their therapies aim to overcome the limitations of conventional CAR-T cells which only target surface proteins. Their lead program, TJJS-001, is a CAR-T therapy targeting GPC3-pMHC for hepatocellular carcinoma and has entered Phase 1 clinical trials. The company is supported by prominent venture capital firms including Qiming Venture Partners and IDG Capital. Tianji Jishi continues to expand its pipeline with innovative CAR-T and TCR-T candidates to address significant unmet needs in oncology.